D. Flesch

Anthranilic acid derivatives as nuclear receptor modulators--development of novel PPAR selective and dual PPAR/FXR ligands.

M. Schubert-Zsilavecz, E. Proschak, D. Merk, 2015, Bioorganic & medicinal chemistry.

Fragmentation of GW4064 led to a highly potent partial farnesoid X receptor agonist with improved drug-like properties.

G. Schneider, H. Stark, M. Schubert-Zsilavecz, 2015, Bioorganic & medicinal chemistry.

SAR studies on FXR modulators led to the discovery of the first combined FXR antagonistic/TGR5 agonistic compound.

M. Schubert-Zsilavecz, D. Merk, A. Kaiser, 2016, Future medicinal chemistry.

Novel prostaglandin receptor modulators: a patent review (2002 – 2012) – part I: non-EP receptor modulators

M. Schubert-Zsilavecz, D. Merk, C. Lamers, 2013, Expert opinion on therapeutic patents.

Novel prostaglandin receptor modulators – Part II: EP receptor modulators; a patent review (2002 – 2012)

M. Schubert-Zsilavecz, D. Merk, C. Lamers, 2013, Expert opinion on therapeutic patents.

Anthranilic acid derivatives as novel ligands for farnesoid X receptor (FXR).

G. Schneider, O. Werz, M. Schubert-Zsilavecz, 2014, Bioorganic & medicinal chemistry.

Nonacidic Farnesoid X Receptor Modulators.

Ewgenij Proschak, Manfred Schubert-Zsilavecz, Daniel Merk, 2017, Journal of medicinal chemistry.

Identification and characterisation of a prototype for a new class of competitive PPARγ antagonists.

N. Ferreirós, B. Brüne, M. Schubert-Zsilavecz, 2015, European journal of pharmacology.

SAR-studies of γ-secretase modulators with PPARγ-agonistic and 5-lipoxygenase-inhibitory activity for Alzheimer's disease.

O. Werz, M. Schubert-Zsilavecz, Isabella Ogorek, 2015, Bioorganic & medicinal chemistry letters.